Valued at a market cap of $348.2 billion, Johnson & Johnson (JNJ) researches, develops, manufactures, and sells various ...
The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood ...
The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); ...
The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...
GEN-1184 is under clinical development by Genmab and currently in Phase II for Triple-Negative Breast Cancer (TNBC).
Although it was receiving revenue from eight products, royalties from Johnson & Johnson (JNJ) subsidiary Janssen’s blockbuster multiple myeloma therapy Darzalex (daratumumab) accounted for 68% ...
Darzalex Faspro improved PFS and OS in high-risk smoldering multiple myeloma, reducing progression or death risk by 51% and death risk by 48%. The AQUILA study showed a superior overall response rate ...
GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report)’s stock price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $21.66 and traded as low as ...
INR:5796. most runs in world cup 2019 CSPC Pharmaceutical Group enters the Science and Technology Innovation Board! 15 blockbuster products target a m ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback